Skip to main content
 Sarah Bridges

Sarah Bridges

Trial Manager

Email
bridgesse@cardiff.ac.uk
Telephone
+44 (0)29 2068 7201
Campuses
6th Floor, Neuadd Meirionnydd, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS

Overview

I am the Trial Manager for the SCOPE2 trial, a multi-centre randomised Phase II/III study of radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiotherapy (with an embedded Phase II study of an additional PET scan informing chemotherapy regimen in patients with poor early response). SCOPE2 is currently open and recruiting.

I also manage the FOLFERA trial, a closed randomised Phase II study of the addition of an endothelin receptor antagonist to the FOLFIRI chemotherapy regimen in patients with metastatic colorectal cancer after failure of an oxaliplatin-containing regimen.

In the autumn of 2020 I was Trial Manager for the Novavax Covid-19 vaccine study at its facility in North Wales in collaboration with Public Health Wales, Health and Care Research Wales, and Betsi Cadwaladr University Health Board. I am also involved in the development of a brain cancer study alongside colleagues in Imperial, and am the co-Principal Investigator of Talking Trials, a Wellcome Trust Public Engagement Proof of Concept project exploring perceptions of clinical trials amongst those from minority ethnic backgrounds living in Riverside, Cardiff. 

Publications

Areas of expertise